



NYSE American

LIFE SCIENCES PRESENTATION

December 2022

Safe HARBOR

The matters discussed in this presentation include forward-looking statements about the business prospects of India Globalization Capital, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes or similar expressions. Forward-looking statements reflect management's current expectations as of the date of this conference call and involve certain risks and uncertainties. The forward-looking statements are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments, and other factors that we believe are appropriate under these circumstances.

As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances. India Globalization Capital, Inc. actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors and the forward-looking statements are not guarantees of performance. Some of the factors that could cause future results to materially differ from recent results or those projected in forward-looking statements are included in our in our filings with the Securities and Exchange Commission (the "SEC"), such as our Annual Report on 10-K filed with the SEC on June 23, 2022. We are under no obligation and expressly disclaim any obligation to update or alter the forward-looking statements, whether as a result of such changes, new information, subsequent events or otherwise.





Two Subsidiaries

1. IGC Pharma

Two drug candidates focused on Alzheimer's disease

2. HH Processors

Focused on women's wellness products and healthy energy seltzers

WHY IGC?

The Promise of IGC-AD1

We believe we are

The **FIRST** natural cannabis-based patent-protected compound that relies on low doses of THC, a psychoactive cannabinoid, and another compound as active agents for the treatment of Alzheimer's disease

The **ONLY** natural THC-based investigational drug candidate currently undergoing FDA trials registered on <https://clinicaltrials.gov/>

DIVERSE GROWTH OPPORTUNITIES

Clear strategic focus

Patent-protected investigational drug candidate IGC-AD1 in Phase 2 trial - **the first human trial using low doses of natural THC** to treat symptoms of dementia in Alzheimer's.

Patent-protected drug candidate TGR-63 is a plaque aggregation inhibitor shown in pre-clinical trials to **reduce neurotoxicity in Alzheimer's cell lines and ameliorate beta-amyloid plaque.**

Holief™: Novel line of wellness products for women by women &
Sunday Seltzer™: Energy drink Line.

Innovation-driven R&D with ability to source and manufacture at scale for both verticals.

Clean capital structure





VERTICALLY INTEGRATED OPERATIONS




Potomac, MD

Headquarters.



Vancouver, WA

cGMP Manufacturing
and Processing facility.



Colombia

Licensed R&D facilities
with legal access to
cannabis.



India

Accounting and
Analytics.

FIRST MOVER ADVANTAGE WITH INTELLECTUAL PROPERTY

TARGET	DESCRIPTION	PATENT PENDING	PATENTS GRANTED
Alzheimer's Disease (IGC-AD1)	Compositions and Methods for Treating CNS Disorders: CNS/Alzheimer Disease	1	2
Alzheimer's Disease (TGR-63)	Self-Assembly of NMI Derivatives and its impact on A β protein	0	2
Epilepsy	Composition and Method for Treating Seizure in cats and dogs	0	1
Epilepsy	Composition and Method for Treating Seizure in humans	1	1
Eating Disorders	Method and Composition for Treating Cachexia and Eating Disorders	1	1
Stuttering & Tourette Syndrome	Stuttering & Tourette Syndrome	1	0
Relieving Fatigue and Restoring Energy	Cannabis Based Methods and Compositions for Relieving Stress and Restoring Calm	2	-
Pain	Method for Treating Pain	1	2

7

9



TWO LEAD CANDIDATES TARGETING ALZHEIMER'S DISEASE (AD)

IGC-AD1

Treatment of Symptoms

Our lead therapeutic candidate entering Phase 2 trials for treating agitation in dementia from Alzheimer's Disease

TGR-63

Treatment of Disease

A plaque aggregation inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer's cell lines and improve memory in AD mouse models

ALZHEIMER'S DISEASE – A CRITICAL UNMET NEED

6.5 Million

Americans with
Alzheimer's Disease in 2022

13.8 Million

Americans with
Alzheimer's Disease by 2050

Fifth-Leading

Cause of death among
Americans Age 65+

\$1 Trillion

Expected total expenses
for Alzheimer's and other dementias by 2050

IGC-AD1

A Promising Therapy for Alzheimer's

Researchers at the University of South Florida discovered the potential for cannabis to play a role in treating Alzheimer's. The discovery was featured on Dr. Sanjay Gupta's CNN show "Weed 2"

In 2017, IGC acquired the exclusive rights to the research data and patent filing. Based on the research we know that IGC-AD1 has promise in slowing the progression of Alzheimer's and improving memory, our short-term strategy is to develop a drug that reduces neuropsychiatric symptoms (NPS) in Alzheimer's

Benefits of Approach

- Accelerate go-to-market of drug with a smaller scope
- Diversify risk by processing longer-term trials on treating AD with shorter term studies on treating symptoms of AD*



PHASE 2 TRIAL FOCUS: AGITATION IN ALZHEIMER'S

76% of Alzheimer's patients suffer from agitation

Emotional distress, verbal and physical aggression, irritability, and disinhibition

Currently there are no FDA-approved medications to alleviate agitation in AD dementia


Ingestion of medical cannabis is considered a better option than inhalation

Inhalation doesn't allow precise quantifying and can adversely impact lung health, leading to irritation, falls, and infections in already compromised patients


Agitation is associated with:

- Higher admission rate to assisted living facilities
- Higher use of medications
- Long-term hospitalization
- Higher mortality

Non-amyloidogenic



Amyloidogenic




OUR PROMISING IGC-AD1 PLATFORM

Pre-clinical studies: decreased plaques and decreased pTau, two hallmarks of Alzheimer's:

- Inhibits the aggregation of amyloid plaque
- Reduces phosphorylated tau (pTau)
- Enhances mitochondrial function
- Non-toxic. Repeated low dosing over 48 hours is non-toxic

MEMORY IMPROVED IN AD (APP/PS1) MOUSE MODEL




AD model mice dosed with the active agent in IGC-AD1 had significantly improved times and less errors in a Morris Water Maze test than those in the control group

- The maze uses spatial cues for mice to navigate a swimming container full of stained water and find a safe platform
- The memory task is assessed in multiple trials to measure how well the mouse finds the platform

IGC-AD1 PHASE 1 TRIAL COMPLETED

Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 in participants with AD & NPS using the NPI (NPS: Neuropsychiatric Systems. NPI: Neuropsychiatric Inventory)



Safety, Tolerability, Agitation, NPS



No life-threatening or serious adverse events at any dosing level



Decrease in agitation by 48% - 67% depending on dosage (NPI agitation scale)



Decrease in depression by 67% - 75% depending on dosage (NPI depression scale)



Phase 1 findings show IGC-AD1 has potential to treat NPS in AD

IGC-AD1 PHASE 2 TRIAL HAS COMMENCED

Placebo Controlled, Double Blind, Randomized, Multi Site

Phase 2 protocol seeks to show that IGC's low dose THC based investigational drug, IGC-AD1, is effective, compared to placebo, in lowering agitation in participants with Alzheimer's

Objective

Evaluate if **IGC-AG1** is superior to placebo in reducing agitation in a six-week trial

Key Inclusion Criteria


Individuals 60 years and above

Diagnosis of **AD** with established and persistent symptomatology in agitation


Sites

5-7 trial sites

Admit a diverse population to look at both the impact of variations of the **gene CYP2C9** that metabolizes THC, as well as **APOE e4**, a gene that increases the risk of getting Alzheimer's



Target Completion: 146 Participants



TGR-63 A PROMISING PATH-BREAKING MOLECULE

IGC acquired exclusive rights to TGR-63 from researchers at India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) who created the TGR-63 molecule.

- Pre-clinical testing demonstrates that **TGR-63 holds potential to ameliorate plaque—one** of the hallmarks of AD.
- Behavioral tests with AD (APP/PS1) mice show that TGR-63 can rescue neuronal cells from amyloid toxicity and **minimize learning deficiency, memory impairment, and cognitive decline.**
- **Current status:** Toxicology and other studies leading to Phase 1 trials in progress.

SR. SCIENTIFIC TRIAL TEAM

Scientific Management

Dr. Varduhi Ghazaryan, MD, MPH
Medical Director



Dr. Saadia Shahnawaz, MD
Medical Director



Dr. Juan Manuel Orjuela, MD
Neuropsychiatrist



Jagadeesh Rao, PhD
Principal Scientist



Diego Rodriguez, PhD
Senior Clinical Researcher



Fabio Mayorga, PhD
Senior Scientist



Evelyn Gutiérrez, Chem Eng.
Scientific Manager



Inventors

Prof. Chuanhai Cao, PhD
Professor of Pharmaceutical Science



Prof. T Govindaraju, PhD, FRSC.
Professor - Bioorganic Chemistry



Scientific Advisors

Dr. L. Elliot Hong, MD
Professor Psychiatrist



Dr. Krista Lanctôt, PhD
Professor & Director of
Neuropsychopharmacology



Dr. James Saunders, PhD
Ret. Professor, Molecular Biology



POTENTIAL TO DRIVE SIGNIFICANT GROWTH

	NORTH AMERICA AND EUROPE		
Individuals with AD	15M	15M	15M
Agitation in AD	11M	11M	11M
% adoption of drug (IGC-AD1)	3%	5%	10%
Annual Price/Patient of drug	\$1,200 – \$2,400	\$1,200 – \$2,400	\$1,200 – \$2,400
Estimated Revenue	\$0.4B – \$0.8B	\$0.6B - \$1.3B	\$1.3B - \$2.6B

Key Market Factors



No FDA approved drugs for the treatment of agitation due to Alzheimer's exist today



Distribution strategy involves **direct to consumer** e-commerce accelerating time-to-market



Accessible at an **affordable price**

HH PROCESSORS

OTC Products
GMP Facilities
Pharma Manufacturing



GMP



Cruelty-Free



Gluten-Free



VEGAN



GROWING FAMILY OF WELLNESS PRODUCTS



WOMEN'S HEALTH & WELLNESS SCIENCE



Vegan



Gluten Free



Paraben Free



Cruelty Free

Non-GMO, vegan line of over-the-counter “OTC” wellness products with natural ingredients **designed for women by women**

PMS, period cramps, fitness, & sleep, Holief™ covers a spectrum of wellness through a line of products that meets the highest standards and values

From living an active lifestyle to handling daily stress, our goal is to give customers tools they need to feel their best

Our vision is to go beyond products, creating a safe space where women can have open conversations about menstruation, sleep, fitness, mindfulness, and nutrition

As Seen In

Women'sHealth

**MARKETS
INSIDER**

HEMISPHERES

SUNDAY™

SELTZER

Energy drinks are **changing the seltzer game**

Low-calorie carbonated energy drink with natural caffeine from green tea extract, hemp (CBD), vitamin B and C, no added sugars and no preservatives

Sunday Seltzer also offers seltzer in four flavors with hemp (CBD), vitamin B, vitamin C, and no caffeine



FROM LAB-TO-MARKET

Unique End-to-end Capabilities

Our formulations

R&D: Ability to source and manufacture product at scale


Brand creation, fulfillment & shipping

E-commerce and data analytics

Global customer engagement through strategic partnerships, social media, and influencers

Affordable and **fast time-to-market**

Sales Beginning To Ramp



SUMMARY

To our knowledge, IGC-AD1 is the **ONLY natural low dose THC-based investigational drug candidate** currently undergoing FDA trials in Alzheimer's

IGC-AD1 Phase 2 Trial has commenced, based on positive findings in Phase 1

Short- and long-term strategies to address Alzheimer's Disease with **significant upside even with modest adoption**

Vertically integrated with the ability to source and manufacture at scale

Clean capital structure



THANK YOU

